Related Experiment Video

Updated: Mar 27, 2026

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

15.8K

Association of the PPARγ2 Pro12Ala polymorphism with increased risk of cardiovascular diseases

Y Li1, J Zhu2, J Q Ding3

  • 1Department of Pharmacy, Ministry of Health Beijing Hospital, Beijing, China.

Genetics and Molecular Research : GMR
|January 20, 2016
PubMed

Insights

The PPARγ2 Pro12Ala polymorphism is linked to an increased risk of cardiovascular disease (CVD), especially myocardial infarction (MI). This genetic variant may serve as an early indicator for CVD development.

Area of Science:

  • Genetics and Cardiovascular Medicine

Background:

  • Cardiovascular disease (CVD) remains a leading cause of mortality worldwide.
  • Genetic factors play a significant role in the susceptibility to CVD.
  • The peroxisome proliferator-activated receptor gamma 2 (PPARγ2) Pro12Ala polymorphism has been investigated for its association with CVD risk.

Purpose of the Study:

  • To conduct a meta-analysis investigating the correlation between the PPARγ2 Pro12Ala polymorphism (rs1801282) and the risk of cardiovascular disease (CVD).
  • To analyze the association across different inheritance models and specific CVD subtypes, including myocardial infarction (MI), coronary artery disease (CAD), and acute coronary syndromes (ACS).

Main Methods:

  • A comprehensive meta-analysis of published case-control studies was performed.
  • Studies were identified through electronic database and manual searches, adhering to strict inclusion criteria.
  • Statistical analyses were conducted using R 3.1.0 and Stata 12.0 software, examining allelic, dominant, homozygous, heterozygous, and recessive models.

Main Results:

  • The meta-analysis included 12 studies with 10,189 CVD patients and 17,899 controls.
  • The PPARγ2 Pro12Ala polymorphism showed a significant correlation with increased CVD risk under allelic and dominant models.
  • A higher risk of MI was associated with the polymorphism under allelic and dominant models, but not with CAD or ACS.

Conclusions:

  • The PPARγ2 Pro12Ala (rs1801282) polymorphism is potentially associated with an elevated risk of developing cardiovascular disease (CVD).
  • This genetic polymorphism appears to be a significant risk factor particularly for myocardial infarction (MI).
  • The PPARγ2 Pro12Ala polymorphism may function as a valuable early indicator for CVD risk stratification.

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.8K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
67
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
89
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.6K
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
113